CINCA syndrome

Disease ID:1026
Name:CINCA syndrome
Associated with:1 targets
0 immuno targets immuno relevant
1 immuno ligands
Chronic infantile neurological cutaneous articular syndrome
Database Links
OMIM: 607115
Orphanet: ORPHA1451



Ligand Approved Immuno References Clinical comments
rilonacept  [ FDA (2008), EMA (2009) ( ]
Clinical Use: Currently used in the treatment of cryopyrin-associated periodic syndrome (CAPS). Cryopyrin-associated periodic syndrome includes three previously distinct disorders: Familial cold autoinflammatory syndrome; Muckle-Wells syndrome; and CINCA syndrome, that are now considered to represent a disease continuum, all caused by NLRP3 protein mutations.

EMA approval has been withdrawn.
Immuno Disease Comments: Approved drug for CINCA syndrome.